Pro Medicus Limited
Pro Medicus Limited (PME.AX) Financial Performance & Income Statement Overview
Explore the financials of Pro Medicus Limited (PME.AX), including yearly and quarterly data on income, cash flow, and balance sheets.
Pro Medicus Limited (PME.AX) Income Statement & Financial Overview
Analyze Pro Medicus Limited’s PME.AX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $97.19M | $87.39M | $74.11M | $68.01M |
| Cost of Revenue | $20.49M | $19.70M | $19.49M | $17.31M |
| Gross Profit | $76.70M | $67.69M | $54.62M | $50.70M |
| Gross Profit Ratio | $0.79 | $0.77 | $0.74 | $0.75 |
| R&D Expenses | $0.00 | $0.00 | $3.97M | $3.62M |
| SG&A Expenses | $6.78M | $4.37M | $5.69M | $4.05M |
| Operating Expenses | $6.78M | $4.37M | $5.69M | $4.05M |
| Total Costs & Expenses | -$27.27M | $24.07M | $25.18M | $21.36M |
| Interest Income | $3.60M | $2.68M | $2.15M | $1.93M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $3.15M | $4.10M | $4.41M | $4.04M |
| EBITDA | $76.43M | $70.44M | $54.57M | $52.06M |
| EBITDA Ratio | $0.79 | $0.81 | $0.72 | $0.75 |
| Operating Income | $69.92M | $63.32M | $48.93M | $46.66M |
| Operating Income Ratio | $0.72 | $0.72 | $0.66 | $0.69 |
| Other Income/Expenses (Net) | $3.35M | $3.02M | $1.23M | $1.16M |
| Income Before Tax | $73.27M | $66.34M | $50.16M | $48.03M |
| Income Before Tax Ratio | $0.75 | $0.76 | $0.68 | $0.71 |
| Income Tax Expense | $21.53M | $19.79M | $13.91M | $14.57M |
| Net Income | $51.74M | $46.54M | $36.25M | $33.46M |
| Net Income Ratio | $0.53 | $0.53 | $0.49 | $0.49 |
| EPS | $0.50 | $0.45 | $0.35 | $0.32 |
| Diluted EPS | $0.49 | $0.45 | $0.35 | $0.32 |
| Weighted Avg Shares Outstanding | $104.47M | $104.42M | $104.43M | $104.43M |
| Weighted Avg Shares Outstanding (Diluted) | $104.66M | $104.59M | $104.74M | $104.47M |
Over the last four quarters, Pro Medicus Limited's revenue moved from $68.01M in Q4 2023 to $97.19M in Q2 2025. Operating income in Q2 2025 was $69.92M, with a strong operating margin of 72%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Pro Medicus Limited remained robust at $76.43M, reflecting operational efficiency. Net income rose to $51.74M, with an EPS of $0.50. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan